ClinicalTrials.gg
CompletedNCT06977815RVEC-DCLUpdated Jul 8, 2026

Non-randomized Clinical Trial on Cognitive Stimulation With Virtual Reality in Patients With Mild Cognitive Impairment

An interventional study of VR-Enhanced Cognitive Rehabilitation and Standard Cognitive Rehabilitation in Mild Cognitive Impairment, Cognitive Dysfunction and Aging, sponsored by Badalona Serveis Assistencials. Completed at 1 site in Spain. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Badalona Serveis Assistencials · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Oct 2024, registered May 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 162 studies in Cognitive Dysfunction with a site in Spain — 44 open to participants now, 61 under way, 9 of them phase 3. Cognitive Dysfunction · Spain.

Enrollment
89th of 127
70 · median 100
Started
2024
with 16 others
No phase
91 of 162
27 open now
Registered
132nd of 162
by date

Among the 162 studies in Cognitive Dysfunction with a site in Spain, this one is the 89th largest by enrollment of the 127 interventional ones that give a count, is one of 17 that started in 2024, is one of 91 with no phase, and was the 132nd registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

44 of the 162 studies in Cognitive Dysfunction with a site in Spain are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Cognitive Dysfunction with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this study is to find out if adding virtual reality (VR) to a cognitive training program helps improve cognitive performance in older adults with mild cognitive impairment (MCI). In this study, all participants will take part in a 12-week computer-based cognitive rehabilitation program. One group will also use immersive VR for 15-20 minutes at the end of each session. Participants will attend 2 sessions per week, completing at least 20 sessions and up to 22, depending on the clinic's schedule. Researchers will measure changes in attention, memory, and thinking skills using standard cognitive tests. They will also collect feedback on how participants experience the VR exercises.

Read the detailed description

This clinical trial evaluates a cognitive rehabilitation program enhanced with virtual reality (VR) for older adults with mild cognitive impairment (MCI). The study investigates whether adding immersive VR exercises to a conventional program improves cognitive performance compared to standard cognitive rehabilitation alone.

All participants take part in a structured, computer-based cognitive training program delivered over 12 weeks. Sessions occur twice per week, with participants completing at least 20 and up to 22 sessions depending on clinic scheduling. The intervention group receives an additional 15-20 minutes of immersive VR content at the end of each session. VR exercises target attention, memory, and executive functioning, aiming to increase engagement and therapeutic value.

This trial complements a previously registered pilot study (ClinicalTrials.gov Identifier: NCT06155721) and builds on its published results.

Cognitive performance will be assessed using standardized neuropsychological tests including the Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), Digit Span, Trail Making Test (TMT), and Symbol Digit Modalities Test (SDMT). Functional capacity will be evaluated using the Lawton-Brody scale. Usability and satisfaction with the VR system will be measured in the intervention group using the System Usability Scale (SUS) and a custom satisfaction questionnaire.

The study was implemented pragmatically within routine clinical care. Allocation followed the pre-existing attendance schedule of the psychogeriatric day hospital. For logistical and ethical reasons related to service implementation, one comparator group was later offered the VR-supported intervention after completing its standard rehabilitation phase and post-intervention assessment. Analyses will distinguish unique participants from rehabilitation episodes to account for this sequential access.

The study has been approved by the Germans Trias i Pujol University Hospital Research Ethics Committee (PI-24-210) and complies with the Declaration of Helsinki and the European General Data Protection Regulation (GDPR).

03

Conditions studied

  • Mild Cognitive Impairment
  • Cognitive Dysfunction
  • Aging

Keywords

  • Virtual Reality
  • Cognitive Rehabilitation
  • Older Adults
  • VR-Enhanced Therapy
  • Neurocognitive Disorders
  • Cognitive Stimulation
  • Gerontology
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adults aged ≥60 years, classified as having mild cognitive impairment or early cognitive impairment, with >20, regularly attending cognitive stimulation sessions at the CSSC day hospital and able to provide or consent through a legal representative.

Exclusion criteria

Exclusion Criteria:

Severe or unstable illness interfering with participation, severe psychiatric symptoms that could be exacerbated by VR, severe visual or hearing impairment preventing participation, high sensitivity to motion sickness, epilepsy, or inability or unwillingness to provide .

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    VR-Enhanced Cognitive Rehabilitation

    Participants receive a computer-based cognitive rehabilitation program supplemented with immersive virtual reality exercises. The program is delivered in two sessions per week over 12 weeks, for a total of approximately 20 to 22 sessions.

    Behavioral: VR-Enhanced Cognitive Rehabilitation

  • Active comparator
    Standard Cognitive Rehabilitation

    Participants receive a standard computer-based cognitive rehabilitation program. The program is delivered in two sessions per week over 12 weeks, for a total of approximately 20 to 22 sessions.

    Behavioral: Standard Cognitive Rehabilitation

Interventions

  • BehavioralVR-Enhanced Cognitive Rehabilitation

    A program consisting of 45-minute computer-based cognitive rehabilitation exercises, enhanced with 15-20 minutes of immersive virtual reality (VR) content per session. The VR component targets memory, attention, and executive function. Sessions are delivered twice per week over 12 weeks.

    Also known as: Virtual Reality Cognitive Support

  • BehavioralStandard Cognitive Rehabilitation

    A program consisting of 45-minute computer-based cognitive rehabilitation exercises targeting memory, attention, and executive function. Sessions are delivered twice per week over 12 weeks. No VR content is included.

    Also known as: Computer-Based Cognitive Training

06

What researchers measure

Primary outcomes

  1. Global Cognition as Measured by the Montreal Cognitive Assessment (MoCA)

    MoCA is a 30-point screening tool for global cognitive function, assessing memory, attention, language, visuospatial skills, and executive function. Score Range: 0 to 30 points \- Higher scores means better global cognition function

    Time frame: Baseline and immediately post-intervention (Week 12, within 1 week after last session)

  2. Global Cognition as Measured by the Mini-Mental State Examination (MMSE)

    MMSE is a 30-point questionnaire evaluating orientation, attention, recall, language, and visual construction Score Range: 0 to 30 points. Higher scores means better global cognition function

    Time frame: Baseline and immediately post-intervention (Week 12, within 1 week after last session)

  3. Short-Term Memory as Measured by the Digit Span Test (Forward Span)

    Forward Digit Span measures verbal short-term memory. Score Range: 0 to 9 points Higher scores reflect better performance.

    Time frame: Baseline and immediately post-intervention (Week 12, within 1 week after last session)

  4. Working Memory as Measured by the Digit Span Test (Backward Span)

    Backward Digit Span assesses working memory and mental manipulation. Score Range: 0 to 9 points. Higher scores indicate better working memory.

    Time frame: Baseline and immediately post-intervention (Week 12, within 1 week after last session)

  5. Visuospatial Attention as Measured by the Trail Making Test Part A (TMT-A)

    TMT-A measures visual attention and processing speed. The outcome is time to completion measured in seconds, typically ranging from several seconds to several minutes. Lower times (faster completion) indicate better visuospatial attention.

    Time frame: Baseline and immediately post-intervention (Week 12, within 1 week after last session)

  6. Executive Function as Measured by the Trail Making Test Part B (TMT-B)

    TMT-B assesses alternating attention and executive control. The outcome is time to completion measured in seconds, typically ranging from several seconds to several minutes. Lower times (faster completion) indicate better alternating attention.

    Time frame: Baseline and immediately post-intervention (Week 12, within 1 week after last session)

  7. Processing Speed as Measured by the Symbol Digit Modalities Test (SDMT)

    SDMT: Symbol Digit Modalities Test. The Symbol Digit Modalities Test (SDMT) measures processing speed, attention, and visual-motor coordination. During the test, participants are required to match abstract symbols with corresponding numbers using a key. The total raw score is calculated as the number of correct symbol-digit pairs completed within a 90-second interval. There is no fixed maximum score, as it varies based on individual performance. Higher scores indicate better processing speed and cognitive performance.

    Time frame: Baseline and immediately post-intervention (Week 12, within 1 week after last session)

  8. Functional Capacity as Measured by the Lawton-Brody Instrumental Activities of Daily Living Scale

    The Lawton-Brody Instrumental Activities of Daily Living Scale evaluates functional independence in activities such as telephone use, shopping, cooking, and managing finances. Scores range from 0 to 8, with higher scores indicating greater independence. Each task is scored as independent (1) or dependent (0).

    Time frame: Baseline and immediately post-intervention (Week 12, within 1 week after last session)

Secondary outcomes

  1. Patient Usability of the VR System as Measured by the Adapted 8-Item System Usability Scale (SUS)

    Participants rate the comfort and tolerability of the Meta Quest 2 or 3 headset after the final session. The scale includes 8 items addressing physical discomfort (e.g., weight, visual strain, dizziness, fatigue, and headache). Score Range: 0 to 100 (converted from Likert responses) Interpretation: Higher scores indicate greater headset tolerability and comfort.

    Time frame: Post-intervention (Week 12, within 1 week after last session)

  2. Patient Comfort and Tolerability of the VR Headset as Measured by an 8-Item Adapted Scale

    Participants rate the comfort and tolerability of the Meta Quest 2 or 3 headset after the final session. The scale includes 8 items addressing physical discomfort (e.g., weight, visual strain, dizziness, fatigue, and headache). Score Range: 0 to 100 (converted from Likert responses) Interpretation: Higher scores indicate greater headset tolerability and comfort.

    Time frame: Post-intervention (Week 12, within 1 week after last session)

  3. Clinician Usability of the VR System as Measured by the Adapted 8-Item System Usability Scale (SUS)

    An adapted SUS completed by professionals delivering the intervention. The 8 items assess perceived usability, integration into clinical workflow, and ease of use for patients. Score Range: 0 to 100 Interpretation: Higher scores indicate better usability.

    Time frame: Post-intervention (Week 12, within 1 week after last session)

  4. Clinician Perception of VR Headset Comfort for Patients as Measured by a 3-Item Questionnaire

    Professionals rate their perception of how comfortable and manageable the VR headset is for patients. The 3 items assess concerns such as weight, usability of controls, and prolonged wear tolerance. Score Range: 0 to 100 (converted from Likert responses) Interpretation: Higher scores indicate better perceived comfort and usability for patients.

    Time frame: Post-intervention (Week 12, within 1 week after last session)

Other outcomes

  1. Participant Age

    Age in years, collected at baseline. Used to describe the study population and for subgroup analysis if needed.

    Time frame: Baseline

  2. Participant Sex

    Self-reported biological sex, categorized as: 0 = Female 1 = Male 3 = Other Collected at baseline to describe participant characteristics.

    Time frame: Baseline

07

Study locations

1 site
  • Centro Socio Sanitario El Carmen
    Badalona, Barcelona 08917, Spain
08

References and documents

Publications

  • Virtual Reality in Cognitive Rehabilitation: A Pilot Study on Usability and Preliminary Clinical Outcomes in Seniors with Mild Cognitive Impairment Jose Ferrer Costa, Maria Jose Ciudad, Maribel González Abad, and José Luis Rodríguez García Journal of Medical Extended Reality 2025 2:1, 30-42

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Apr 2026, 18 months.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 18 months is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2025
First posted
May 18, 2025
StartActual
Oct 4, 2024
Primary completionActual
Apr 29, 2026
CompletionActual
May 22, 2026
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06977815
Lead sponsor
Badalona Serveis Assistencials
Responsible party
Jose Ferrer Costa (Medical Researcher and Project Manager, Badalona Serveis Assistencials) — Principal investigator
First posted
May 18, 2025
Start date
Oct 4, 2024
Primary completion
Apr 29, 2026
Completion
May 22, 2026
Last update
Jul 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion